Dexxon Holdings Ltd. 4
4 · Roivant Sciences Ltd. · Filed Apr 26, 2022
Insider Transaction Report
Form 4
Dexcel Pharma Technologies Ltd.
10% Owner
Transactions
- Purchase
Common Shares
2022-04-22$3.83/sh+31,685$121,319→ 98,840,843 total - Purchase
Common Shares
2022-04-25$3.91/sh+8,600$33,635→ 98,849,443 total
Footnotes (4)
- [F1]Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.
- [F2]The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.685 to $3.88.
- [F3]The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.825 to $3.99.
- [F4]The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.